Context: Fibroblast growth factor (FGF)19 and FGF21 are secreted by the intestine and liver in response to macronutrient intake. Intestinal resection and reconstruction via bariatric surgery may alter their regulation. Objective: We tested the hypothesis that weight loss induced by Roux-en-Y gastric bypass (RYGB) surgery, but not matched weight loss induced by laparoscopic adjustable gastric banding (LAGB), increases postprandial plasma FGF19 and FGF21 concentrations. Design: Glucose kinetics and plasma FGF19 and FGF21 responses to mixed meal ingestion and to glucose-insulin infusion during a hyperinsulinemic-euglycemic clamp procedure, with stable isotope tracer methods, were evaluated in 28 adults with obesity before and after 20% weight loss induced by RYGB (n = 16) or LAGB (n = 12). Results: LAGB- and RYGB-induced weight loss increased postprandial plasma FGF19 concentrations (P < 0.05). However, weight loss after RYGB, but not LAGB, increased postprandial plasma FGF21 concentrations (1875 ± 330 to 2976 ± 682 vs 2150 ± 310 and 1572 ± 265 pg/mL × 6 hours, respectively). The increase in plasma FGF21 occurred ∼2 hours after the peak in delivery of ingested glucose into systemic circulation. Glucose-insulin infusion increased plasma FGF21, but not FGF19, concentrations. The increase in plasma FGF21 during glucose-insulin infusion was greater after than before weight loss in both surgery groups without a difference between groups, whereas plasma FGF19 was not affected by either procedure. Conclusions: RYGB-induced weight loss has unique effects on postprandial FGF21 metabolism, presumably due to rapid delivery of ingested macronutrients to the small intestine and delivery of glucose to the liver.
Context:Fibroblast growth factor (FGF)19 and FGF21 are secreted by the intestine and liver in response to macronutrient intake. Intestinal resection and reconstruction via bariatric surgery may alter their regulation. Objective: We tested the hypothesis that weight loss induced by Roux-en-Y gastric bypass (RYGB) surgery, but not matched weight loss induced by laparoscopic adjustable gastric banding (LAGB), increases postprandial plasma FGF19 and FGF21 concentrations. Design: Glucose kinetics and plasma FGF19 and FGF21 responses to mixed meal ingestion and to glucose-insulin infusion during a hyperinsulinemic-euglycemic clamp procedure, with stable isotope tracer methods, were evaluated in 28 adults with obesity before and after 20% weight loss induced by RYGB (n = 16) or LAGB (n = 12). Results: LAGB- and RYGB-induced weight loss increased postprandial plasma FGF19 concentrations (P < 0.05). However, weight loss after RYGB, but not LAGB, increased postprandial plasma FGF21 concentrations (1875 ± 330 to 2976 ± 682 vs 2150 ± 310 and 1572 ± 265 pg/mL × 6 hours, respectively). The increase in plasma FGF21 occurred ∼2 hours after the peak in delivery of ingested glucose into systemic circulation. Glucose-insulin infusion increased plasma FGF21, but not FGF19, concentrations. The increase in plasma FGF21 during glucose-insulin infusion was greater after than before weight loss in both surgery groups without a difference between groups, whereas plasma FGF19 was not affected by either procedure. Conclusions: RYGB-induced weight loss has unique effects on postprandial FGF21 metabolism, presumably due to rapid delivery of ingested macronutrients to the small intestine and delivery of glucose to the liver.
Authors: Torsten Olbers; Sofia Björkman; Ak Lindroos; Almantas Maleckas; Lars Lönn; Lars Sjöström; Hans Lönroth Journal: Ann Surg Date: 2006-11 Impact factor: 12.969
Authors: Susanna Søberg; Camilla H Sandholt; Naja Z Jespersen; Ulla Toft; Anja L Madsen; Stephanie von Holstein-Rathlou; Trisha J Grevengoed; Karl B Christensen; Wender L P Bredie; Matthew J Potthoff; Thomas P J Solomon; Camilla Scheele; Allan Linneberg; Torben Jørgensen; Oluf Pedersen; Torben Hansen; Matthew P Gillum; Niels Grarup Journal: Cell Metab Date: 2017-05-02 Impact factor: 27.287
Authors: Samantha M Solon-Biet; Victoria C Cogger; Tamara Pulpitel; Marika Heblinski; Devin Wahl; Aisling C McMahon; Alessandra Warren; Jessica Durrant-Whyte; Kirsty A Walters; James R Krycer; Fleur Ponton; Rahul Gokarn; Jibran A Wali; Kari Ruohonen; Arthur D Conigrave; David E James; David Raubenheimer; Christopher D Morrison; David G Le Couteur; Stephen J Simpson Journal: Cell Metab Date: 2016-09-29 Impact factor: 27.287
Authors: Gregory J Morton; Karl J Kaiyala; Karen E Foster-Schubert; David E Cummings; Michael W Schwartz Journal: J Clin Endocrinol Metab Date: 2013-12-02 Impact factor: 5.958
Authors: Elisa Fabbrini; Faidon Magkos; B Selma Mohammed; Terri Pietka; Nada A Abumrad; Bruce W Patterson; Adewole Okunade; Samuel Klein Journal: Proc Natl Acad Sci U S A Date: 2009-08-24 Impact factor: 11.205
Authors: C Dirksen; M Damgaard; K N Bojsen-Møller; N B Jørgensen; U Kielgast; S H Jacobsen; L S Naver; D Worm; J J Holst; S Madsbad; D L Hansen; J L Madsen Journal: Neurogastroenterol Motil Date: 2013-01-29 Impact factor: 3.598
Authors: Christopher M Mulla; Allison B Goldfine; Jonathan M Dreyfuss; Sander Houten; Hui Pan; David M Pober; Nicolai J Wewer Albrechtsen; Maria S Svane; Julie B Schmidt; Jens Juul Holst; Colleen M Craig; Tracey L McLaughlin; Mary-Elizabeth Patti Journal: Obes Surg Date: 2019-07 Impact factor: 4.129
Authors: James Casella-Mariolo; Lidia Castagneto-Gissey; Giulia Angelini; Andrea Zoli; Pierluigi Marini; Stefan R Bornstein; Dimitri J Pournaras; Francesco Rubino; Carel W le Roux; Geltrude Mingrone; Giovanni Casella Journal: EBioMedicine Date: 2019-08-07 Impact factor: 8.143
Authors: Mette S Nielsen; Susanna Søberg; Julie B Schmidt; Anne Chenchar; Anders Sjödin; Matthew P Gillum Journal: PeerJ Date: 2021-04-14 Impact factor: 2.984